Australia markets open in 4 hours 40 minutes

ChemoCentryx, Inc. (CCXI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
51.87-0.00 (-0.01%)
As of 02:20PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 3.73B
Enterprise value 3.47B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)98.33
Price/book (mrq)15.77
Enterprise value/revenue 93.38
Enterprise value/EBITDA -27.45

Trading information

Stock price history

Beta (5Y monthly) 1.24
52-week change 3179.02%
S&P500 52-week change 3-13.12%
52-week high 351.89
52-week low 314.95
50-day moving average 347.37
200-day moving average 331.09

Share statistics

Avg vol (3-month) 32.39M
Avg vol (10-day) 31.56M
Shares outstanding 571.92M
Implied shares outstanding 6N/A
Float 858.98M
% held by insiders 112.01%
% held by institutions 183.56%
Shares short (14 Sept 2022) 47.27M
Short ratio (14 Sept 2022) 43.91
Short % of float (14 Sept 2022) 410.58%
Short % of shares outstanding (14 Sept 2022) 410.11%
Shares short (prior month 14 Aug 2022) 46.91M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 June 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-353.17%

Management effectiveness

Return on assets (ttm)-18.55%
Return on equity (ttm)-46.96%

Income statement

Revenue (ttm)37.28M
Revenue per share (ttm)0.53
Quarterly revenue growth (yoy)548.80%
Gross profit (ttm)-51.07M
EBITDA -127.6M
Net income avi to common (ttm)-133.09M
Diluted EPS (ttm)-2.01
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)328.62M
Total cash per share (mrq)4.61
Total debt (mrq)73.2M
Total debt/equity (mrq)30.95
Current ratio (mrq)4.54
Book value per share (mrq)3.32

Cash flow statement

Operating cash flow (ttm)-53.5M
Levered free cash flow (ttm)-53.11M